Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ruzasvir - Atea Pharmaceuticals

Next Previous
Drug Profile

Ruzasvir - Atea Pharmaceuticals

Alternative Names: MK-8408; RZR

Latest Information Update: 09 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merck Sharp & Dohme
  • Developer Atea Pharmaceuticals; Merck Sharp & Dohme
  • Class Antivirals; Benzoxazines; Carbamates; Cyclopropanes; Esters; Imidazoles; Indoles; Pyrrolidines; Thiazoles
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hepatitis C

Most Recent Events

  • 15 Nov 2024 Efficacy data from a phase II trial in Hepatitis C infection presented at the Liver Meeting 2024 75th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2024)
  • 04 Nov 2024 Atea Pharmaceuticals completes enrolment in its phase II trial in Hepatitis C (Combination therapy) in USA, Brazil, Canada, India, South Korea, Mauritius, Moldova, Pakistan, Philippines, Romania, South Africa and Turkey (PO) (NCT05904470)
  • 05 Jun 2024 Adverse events data from the phase II trial in Hepatitis C presented at the European Association for the Study of the Liver Congress (EASL-2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top